Rheumatoid arthritis: is serum vitamin B12 high in active disease?
Grindulis, K.A.; Calverley, M.; Cox, C.
Journal of Rheumatology 11(2): 211-212
1984
ISSN/ISBN: 0315-162X PMID: 6144796 Document Number: 231906
Seven clinical and laboratory indices of disease activity were compared with serum vitamin B12 levels in 32 patients with rheumatoid arthritis treated with penicillamine (16 patients) or sulphasalazine (16 patients) for up to 24 weeks. Prior to treatment each patient had active disease but a normal or low serum vitamin B12 concentration. During treatment, significant improvements occurred in all clinical and laboratory measurements but vitamin B12 levels were unchanged. We have been unable to confirm a reported positive association between rheumatoid disease activity and serum B12 concentration.
Document emailed within 1 workday
Related Documents
Ma, J.; Wang, X.; Mo, Y.; Chen, L.; Zheng, D.; Wei, X.; Dai, L. 2015: Value of serum matrix metalloproteinase-3 in the assessment of active disease in patients with rheumatoid arthritis Zhonghua Yi Xue Za Zhi 95(47): 3823-3828Grieble, H.; Bach, G.; Anderson, T.; Zschocke, R. 1971: Standardization of the latex fixation test for the demonstration of the rheumatoid factor. 3. Nature of the rheumatoid factor in normal serum, in serum of patients with rheumatoid arthritis, and in serum of the aged Acta Biologica et Medica Germanica 26(1): 185-191
Marhoffer, W.; Schatz, H.; Stracke, H.; Ullmann, J.; Schmidt, K.; Federlin, K. 1991: Serum osteocalcin levels in rheumatoid arthritis: a marker for accelerated bone turnover in late onset rheumatoid arthritis Journal of Rheumatology 18(8): 1158-1162
Svenson, K.L.; Lithell, H.; Hällgren, R.; Selinus, I.; Vessby, B. 1987: Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity Archives of Internal Medicine 147(11): 1912-1916
Abu Al Fadl, E.M.; Fattouh, M.; Allam, A.A. 2013: High IL-23 level is a marker of disease activity in rheumatoid arthritis Egyptian Journal of Immunology 20(2): 85-92
Chen, J.R.; Takahashi, M.; Suzuki, M.; Kushida, K.; Miyamoto, S.; Inoue, T. 1998: Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis Journal of Rheumatology 25(12): 2440-2444
Cheung, N.T.; Dawes, P.T.; Poulton, K.V.; Ollier, W.E.; Taylor, D.J.; Mattey, D.L. 2000: High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis Journal of Rheumatology 27(4): 882-887
Bathari, L.; Kotokey, R.K.; Chaliha, M.S. 2016: A study of cardiovascular involvement in cases of rheumatoid arthritis with high disease activity Journal of the Association of Physicians of India 64(1): 151-152
Tebib, J.G.; Boughaba, H.; Letroublon, M.C.; Bienvenu, J.; Noel, E.; Armanet, P.; Colson, F.; Roullet, A.; Bouvier, M. 1991: Serum IL-2 level in rheumatoid arthritis: correlation with joint destruction and disease progression European Cytokine Network 2(4): 239-243
Kitamura, A. 1994: Study of the effects of a new vitamin D3 derivative on type Ii collagen-induced arthritis in an experimental rat model of rheumatoid arthritis Nihon Seikeigeka Gakkai Zasshi 68(12): 1068-1080
Louthrenoo, W.; Kongtawelert, P.; Sivasomboon, C.; Sukitawut, W. 2001: Correlation between serum hyaluronan and disease activity and severity in Thai patients with rheumatoid arthritis Journal of the Medical Association of Thailand 84(5): 622-627
Le Loët, X.; Nordström, D.; Rodriguez, M.; Rubbert, A.; Sarzi-Puttini, P.; Wouters, J.M.G.W.; Woolley, J.Michael.; Wright, N.; Lawrence, C.; Appleton, B. 2008: Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial Journal of Rheumatology 35(8): 1538-1544
Ichikawa, Y.; Yamada, C.; Horiki, T.; Hoshina, Y.; Uchiyama, M. 1998: Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis Clinical and Experimental Rheumatology 16(5): 533-540
Stankovic, A.; Slavic, V.; Stamenkovic, B.; Kamenov, B.; Bojanovic, M.; Mitrovic, D.R. 2009: Serum and synovial fluid concentrations of CCL2 (MCP-1) chemokine in patients suffering rheumatoid arthritis and osteoarthritis reflect disease activity Bratislavske Lekarske Listy 110(10): 641-646
Rana, A.; Gogna, A.; Kabi, B.C. 2020: A study to correlate the serum levels of interleukin 6 with the disease activity indices (CDAi and DAS28 ESR) in seropositive rheumatoid arthritis patients Journal of the Association of Physicians of India 68(1): 69
Sánchez, T.; Contreras-Yáñez, Iú.; Elías-López, D.; Aguilar Salinas, C.A.; Pascual-Ramos, V. 2014: Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs Clinical and Experimental Rheumatology 32(4): 509-515
Doube, A. 2000: Vitamin D deficiency and rheumatoid arthritis New Zealand Medical Journal 113(1112): 259
Sundrarjun, T.; Komindr, S.; Archararit, N.; Dahlan, W.; Puchaiwatananon, O.; Angthararak, S.; Udomsuppayakul, U.; Chuncharunee, S. 2004: Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis Journal of International Medical Research 32(5): 443-454
Goodwin, J.S.; Ceuppens, J.L.; Rodriguez, M.A. 1983: Administration of nonsteroidal anti-inflammatory agents in patients with rheumatoid arthritis. Effects on indexes of cellular immune status and serum rheumatoid factor levels JAMA 250(18): 2485-2488
Kuuliala, A.; Leirisalo-Repo, M.; Möttönen, T.; Hannonen, P.; Nissilä, M.; Kautiainen, H.; Korpela, M.; Julkunen, H.; Hakola, M.; Repo, H. 2005: Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug Clinical and Experimental Rheumatology 23(2): 243-246